```html

Zollinger‑Ellison Syndrome (Gastrinoma) – A Comprehensive Medical Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder characterized by one or more gastrin‑producing tumors (known as gastrinomas) that cause the stomach to release excessive amounts of gastric acid. The hyperacidic environment leads to severe peptic ulcers, diarrhea, and malabsorption. ZES accounts for only about 0.1 %–0.5 % of all peptic ulcer disease cases and affects roughly 1–3 people per million annually.<sup>[1] Mayo Clinic</sup>

Both genders are equally affected, and the condition can appear at any age, but the median age at diagnosis is 45–55 years. Around 25 %–30 % of cases are associated with the inherited condition multiple endocrine neoplasia type 1 (MEN 1).<sup>[2] NIH</sup>

Symptoms

Symptoms result from massive acid production and the presence of the tumor(s). They may develop gradually or present suddenly.

Gastro‑intestinal Manifestations

• Recurrent or refractory peptic ulcers – often multiple, located beyond the duodenum (jejunum, ileum).
• Abdominal pain – cramping, burning, or gnawing pain that may improve with food.
• Diarrhea – watery, sometimes fatty (steatorrhea) due to malabsorption of fats.
• Nausea & vomiting – may be triggered by acid overload.
• Upper gastrointestinal bleeding – melena or hematemesis from ulcer erosion.

Systemic and Metabolic Signs

• Weight loss – secondary to malabsorption, chronic diarrhea, and loss of appetite.
• Fatigue – from anemia, electrolyte disturbances, or vitamin deficiencies.
• Osteopenia/Osteoporosis – chronic acid can increase calcium loss.

Signs Related to the Tumor Itself

• Abdominal mass or fullness – if the gastrinoma grows large.
• Hormonal syndromes – in MEN 1, patients may also have hyperparathyroidism or pituitary tumors.

Causes and Risk Factors

Primary Cause

ZES is caused by a gastrinoma, most commonly arising in the “gastrinoma triangle” (duodenum, pancreas, and the porta hepatis). These tumors are usually malignant (≈60 % are malignant at diagnosis) and may secrete gastrin autonomously.

Genetic Risk Factors

• Multiple endocrine neoplasia type 1 (MEN 1) – an autosomal‑dominant mutation in the MEN1 gene. Up to one‑third of ZES patients have MEN 1.
• Familial gastrinoma – rare inherited form without other MEN 1 features.

Other Potential Risk Factors

• Age > 30 years (median diagnosis 45–55 y).
• Male or female – no strong gender predilection.
• Chronic Helicobacter pylori infection – does not cause ZES but can coexist and worsen ulcer disease.

Diagnosis

Diagnosing ZES requires confirming both hypergastrinemia and acid hypersecretion, then locating the tumor.

1. Biochemical Tests

• Fasting serum gastrin level – > 1000 pg/mL is highly suggestive; levels > 150 pg/mL with a gastric pH < 2 support the diagnosis.
• Gastric pH measurement – obtained via nasogastric aspiration; a pH ≤ 2 confirms acid hypersecretion.
• Secretin stimulation test – paradoxical rise in gastrin after IV secretin is diagnostic when fasting gastrin is 100–1000 pg/mL.

2. Imaging Studies (Tumor Localization)

• Contrast‑enhanced CT or MRI of the abdomen – first‑line for detecting pancreatic or duodenal masses.
• Endoscopic ultrasound (EUS) – high sensitivity for small duodenal lesions.
• Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT – detects metastatic or occult gastrinomas.
• Selective arterial secretin stimulation test – used when imaging is negative but biochemical evidence is strong.

3. Endoscopic Evaluation

Upper endoscopy (EGD) identifies ulcer location, number, and severity, and allows biopsies to rule out malignancy.

4. Genetic Testing

If MEN 1 is suspected (family history, other endocrine tumors), testing for MEN1 mutations is recommended.

Treatment Options

Management has two parallel goals: control acid hypersecretion and remove or control the tumor.

Acid‑Control Medications

• High‑dose Proton Pump Inhibitors (PPIs) – e.g., omeprazole 60–120 mg/day or equivalent; most patients achieve symptom control.
• Histamine‑2 receptor antagonists (H2‑blockers) – less effective alone but may be used adjunctively.
• Potassium‑competitive acid blockers (e.g., vonoprazan) – emerging data show rapid acid suppression; not yet FDA‑approved for ZES in the US.

Long‑term PPI therapy is generally safe, but periodic monitoring of bone density, magnesium, and vitamin B12 is advised.

Surgical Management

• Curative resection – enucleation or pancreaticoduodenectomy for localized gastrinomas; preferred when disease is limited.
• Debulking surgery – for metastatic disease; reduces tumor burden and gastrin output.
• Enucleation of duodenal gastrinomas – often successful because many are small (<2 cm).

Medical Therapy for Unresectable/Metastatic Disease

• Somatostatin analogues (octreotide, lanreotide) – inhibit gastrin secretion and may shrink tumors.
• Targeted therapy – everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) for progressive neuroendocrine tumors.
• Chemotherapy – rarely used; reserved for high‑grade, rapidly progressive disease.
• Peptide receptor radionuclide therapy (PRRT) – 177Lu‑DOTATATE for somatostatin‑receptor positive tumors.

Lifestyle & Supportive Measures

• Small, frequent meals; avoid foods that trigger acid (spicy, fatty, caffeine).
• Stay hydrated to compensate for diarrhea.
• Supplement calcium, vitamin D, and magnesium if long‑term PPI use.
• Smoking cessation and limiting alcohol reduce ulcer risk.

Living with Zollinger‑Ellison Syndrome (gastrinoma)

Daily Management Tips

• Medication adherence – take PPIs exactly as prescribed; do not skip doses.
• Regular follow‑up – labs (gastrin, electrolytes, vitamin B12) every 6‑12 months; imaging annually or sooner if symptoms change.
• Monitor for nutrient deficiencies – check bone density every 2–3 years; supplement as needed.
• Track stool frequency and consistency – worsening diarrhea may signal tumor progression.
• Maintain a symptom diary – note ulcer pain, medication side effects, weight changes.
• Psychosocial support – join support groups (e.g., NET Patient Foundation) and consider counseling.

Dietary Recommendations

1. Eat low‑fat, low‑spice meals; prioritize lean protein, whole grains, and cooked vegetables.
2. Limit caffeinated beverages, carbonated drinks, and citrus juices that may aggravate acidity.
3. Incorporate probiotic‑rich foods (yogurt, kefir) if tolerated, to help gut flora.
4. Consider medium‑chain triglyceride (MCT) oil as a calorie source if fat malabsorption is severe.

Physical Activity

Moderate exercise (30 min most days) supports bone health and overall well‑being, but avoid strenuous activity during active ulcer pain.

Prevention

Because ZES is largely driven by tumor biology, primary prevention is limited. However, risk can be reduced through:

• **Genetic counseling** for families with MEN 1 or known gastrinoma mutations.
• **Avoiding chronic H. pylori infection** – test and treat if positive, which may lessen ulcer burden.
• **Routine surveillance** in MEN 1 carriers (annual gastrin level, imaging) to detect gastrinomas early.
• **Healthy lifestyle** – smoking cessation, limiting alcohol, and a balanced diet support overall gastrointestinal health.

Complications

If untreated or inadequately controlled, ZES can lead to serious complications:

• Perforated ulcer – emergent abdominal pain, peritonitis.
• Severe gastrointestinal bleeding – can cause anemia or hypovolemic shock.
• Intestinal obstruction – from ulcer scarring or tumor mass effect.
• Malabsorption & Nutrient deficiencies – especially fat‑soluble vitamins (A, D, E, K).
• Metastatic disease – liver, lymph nodes, or distant sites; worsens prognosis.
• Bone demineralization – chronic acid loss can lead to osteoporosis and fractures.

Overall 5‑year survival is about 85 % for localized disease but drops to 30‑40 % when distant metastases are present.<sup>[3] Cleveland Clinic</sup>

When to Seek Emergency Care

---

```